{"id":877744,"date":"2025-08-21T03:57:13","date_gmt":"2025-08-21T07:57:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/"},"modified":"2025-08-21T03:57:13","modified_gmt":"2025-08-21T07:57:13","slug":"srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/","title":{"rendered":"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group Before the Final Deadline – SRPT"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n LOS ANGELES<\/span>
\n <\/span>, Aug. 21, 2025<\/span><\/span> \/PRNewswire\/ — The DJS Law Group<\/a>\u00a0reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) for violations of the federal securities laws.<\/p>\n

Shareholders\u00a0who purchased the Company’s securities between June 22, 2023<\/span> and June 24, 2025<\/span>, inclusive (the “Class Period”), are encouraged to contact the firm before August 25, 2025<\/span>.<\/p>\n

\n CASE DETAILS:<\/b>\u00a0\u00a0The complaint alleges<\/span> that the Company made false and misleading statements to the market concerning Sarepta leading investors to believe that its ELEVIDYS therapy was both safe and had potential for approval in wider applications. The Company allegedly<\/span> misled the market about its revenue outlook on ELEVIDYS. The Company also positioned the therapy as having strong growth potential due to a lack of hindrances to broader use.<\/p>\n

If you are a shareholder who suffered a loss,\u00a0contact us to participate<\/a>.<\/p>\n

\n WHY DJS LAW GROUP?<\/b>\u00a0DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic\/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\n CONTACT:<\/b>\n <\/p>\n

\n David J. Schwartz<\/span>\n <\/p>\n

DJS Law Group<\/p>\n

274 White Plains Road, Suite 1<\/p>\n

\u00a0Eastchester, NY 10709<\/p>\n

Phone: 914-206-9742<\/p>\n

Email:\u00a0David@djslawllp.com<\/a><\/p>\n

\n \"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit—contact-the-djs-law-group-before-the-final-deadline—srpt-302535418.html<\/a><\/p>\n

SOURCE DJS Law Group LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LOS ANGELES , Aug. 21, 2025 \/PRNewswire\/ — The DJS Law Group\u00a0reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders\u00a0who purchased the Company’s securities between June 22, 2023 and June 24, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before August 25, 2025. CASE DETAILS:\u00a0\u00a0The complaint alleges that the Company made false and misleading statements to the market concerning Sarepta leading investors to believe that its ELEVIDYS therapy was both safe and had potential for approval in wider applications. The Company allegedly misled the market about its revenue outlook on ELEVIDYS. The Company also positioned the therapy as having … <\/p>\n

Continue reading “SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group Before the Final Deadline – SRPT”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-877744","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LOS ANGELES , Aug. 21, 2025 \/PRNewswire\/ — The DJS Law Group\u00a0reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders\u00a0who purchased the Company’s securities between June 22, 2023 and June 24, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before August 25, 2025. CASE DETAILS:\u00a0\u00a0The complaint alleges that the Company made false and misleading statements to the market concerning Sarepta leading investors to believe that its ELEVIDYS therapy was both safe and had potential for approval in wider applications. The Company allegedly misled the market about its revenue outlook on ELEVIDYS. The Company also positioned the therapy as having … Continue reading "SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group Before the Final Deadline – SRPT"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T07:57:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA56306&sd=2025-08-21\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group Before the Final Deadline – SRPT\",\"datePublished\":\"2025-08-21T07:57:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/\"},\"wordCount\":289,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA56306&sd=2025-08-21\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/\",\"name\":\"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA56306&sd=2025-08-21\",\"datePublished\":\"2025-08-21T07:57:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA56306&sd=2025-08-21\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA56306&sd=2025-08-21\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group Before the Final Deadline – SRPT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/","og_locale":"en_US","og_type":"article","og_title":"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT - Market Newsdesk","og_description":"PR Newswire LOS ANGELES , Aug. 21, 2025 \/PRNewswire\/ — The DJS Law Group\u00a0reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders\u00a0who purchased the Company’s securities between June 22, 2023 and June 24, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before August 25, 2025. CASE DETAILS:\u00a0\u00a0The complaint alleges that the Company made false and misleading statements to the market concerning Sarepta leading investors to believe that its ELEVIDYS therapy was both safe and had potential for approval in wider applications. The Company allegedly misled the market about its revenue outlook on ELEVIDYS. The Company also positioned the therapy as having … Continue reading \"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group Before the Final Deadline – SRPT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-21T07:57:13+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA56306&sd=2025-08-21","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group Before the Final Deadline – SRPT","datePublished":"2025-08-21T07:57:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/"},"wordCount":289,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA56306&sd=2025-08-21","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/","name":"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA56306&sd=2025-08-21","datePublished":"2025-08-21T07:57:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA56306&sd=2025-08-21","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA56306&sd=2025-08-21"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group Before the Final Deadline – SRPT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/877744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=877744"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/877744\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=877744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=877744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=877744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}